CASE REPORT

Complete remission of Cdx-2 positive primary testicular carcinoid tumor: 10-years follow-up and literature review

Eugen Widmeier, Hannah Füllgraf and Cornelius F. Waller

Abstract

Background: The neuroendocrine cells can cause a variety of malignancies throughout the human body known as the neuroendocrine tumors (NETs) or carcinoid tumors. The primary testicular carcinoid tumor (PTCT) accounts for less than 1% of the testicular neoplasms and for only 0.2% of all carcinoid tumors representing already a very rare neoplastic entity. Here, we present a patient with a history of an exceptionally rare primary testicular carcinoid tumor, staining positive for Cdx-2 along with a literature review.

Case presentation: A 44-year old patient without significant past medical history was diagnosed in September 2009 with primary testicular carcinoid tumor, which was surprisingly staining positively for Cdx-2, too. At the time of the initial diagnosis the tumor was already showing histopathological infiltration of veins. DOTA-TATE-PET/CT imaging and endoscopy studies did not show any signs of distant metastases and in particular no gastrointestinal manifestation following no further medical indication for systemic chemotherapy. The continuous and close follow-up of the patient has reached a total of over 10 years at the time of publication remaining in complete remission.

Conclusion: The diagnosis of primary testicular carcinoid is based on histopathology. The detailed histopathologic assessment of biomarkers based on immunohistochemistry is very important for the classification and the prognosis of the primary testicular carcinoid tumor. Primary testicular carcinoid tumor with Cdx-2 positive stain outlines an exceptionally rare neoplastic entity without a consensus about general follow-up guidelines, requiring close clinical and imaging aftercare and consideration in Cdx-2 positive metastatic tumor of unknown origin.

Keywords: Neuroendocrine tumor, Primary testicular carcinoid tumor, Histopathology, Biomarkers, Cdx-2 positivity, Metastatic tumor of unknown origin, Case report

Background

The neuroendocrine cells can cause a variety of malignancies throughout the human body known as the neuroendocrine tumors (NETs). These types of tumors, likewise called carcinoid tumors, are able to produce hormone-like molecules, which can mimic characteristic hormonal syndromes [1]. Carcinoid tumors occur predominantly in the gastrointestinal tract (67.5%) and in the bronchopulmonary system (25.3%) [2]. The primary testicular carcinoid tumor (PTCT) accounts for less than 1% of the testicular neoplasms [3] and for only 0.2% of all carcinoid tumors representing a very rare neoplastic entity [4, 5]. The distinction of the origin in primary or metastatic circumstance is of the utmost importance for the prognosis of the testicular carcinoid tumor and the treatment [6]. Here, we present a case history of a primary testicular carcinoid tumor with exceptionally rare Cdx-2 positive stain and complete remission along
with 10 years recurrence-free follow-up and a literature review.

**Case presentation**
We report a 44-year old patient, who saw his urologist in September 2009 due to a painless and for approximately 6 month continuously growing left testicular swelling. The patient did not report any further clinical signs or symptoms of general disease especially no history of sudden hot flushes. The past medical history reveals solely strumectomy due to Grave’s disease and atopic diathesis.

On clinical exam no additional noticeable problems aside the one-sided testicular mass, especially no inguinal lymphadenopathy, were detected. The complete blood count and metabolic panel studies were all in normal range. Due to suspected testicular malignancy on clinical exam the patient underwent a near-time radical inguinal left-sided orchiectomy. The histological analysis of the testicular tissue revealed the diagnosis of a primary testicular carcinoid tumor, which was positive for chromogranin A, CD56, Ep4 and Cdx-2. The nuclear MIB-1 expression was detected in patches of the tumor cells

![Histological and immunohistochemical analysis of primary testicular carcinoid tumor tissue. Histological analysis (H&E staining) shows nested cuboidal cells with prominent round nuclei and reduced amount of cytoplasm, arranged in a ribbon-like structure and surrounded by moderate fibrotic stroma (a), with a positive immunohistochemical staining for Chromogranin A (b), CD56 (c), Ep-4 (d), Cdx-2 (e) and Mib-1 (f) pointed out by arrows. Scale bars 100 μm](image)
with an MIB-1 index of approximately 2% (Fig. 1). At the
time of the initial diagnosis the tumor was already show-
ing histopathological infiltration of veins (cN0, cM0, R0
and V1). However the 24-h urine study showed a nor-
mal level of 5-Hydroxyindolacetic acid. Based on these
findings the patient subsequently underwent DOTA-
TATE-PET/CT imaging and endoscopy studies showing
no signs of distant metastases and in particular no gas-
trointestinal manifestation following no further medical
indication for systemic chemotherapy. Furthermore the
patient was undergoing continuous clinical, abdomi-
nal sonography and imaging postsurgical care (Fig. 2).
The follow-up of the patient has reached a total of over
10 years at the time of publication remaining in complete
remission.

Discussion
Historically, the nomenclature of “carcinoid” was describ-
ing the tumor entity of neuroendocrine cells with low
malignancy in the gastrointestinal tract (GI) [7]. However
the histopathogenesis of the primary testicular carcinoid
remains under debate suggesting respective hypothesis:
originating from the same precursor cell as the Leydig
cells do or resulting from chromosomal irregularity [8,
9]. The diagnosis of primary testicular carcinoid is based
on histopathology. The detailed histopathologic assess-
ment is very important for the classification and the
prognosis of the primary testicular carcinoid tumor [3].
Mitotic activity and vascular or tunica albuginea inva-
sion were found not to increase the malignancy of the
carcinoid tumors. However the occurrence of a low-
degree of tumor differentiation, symptoms of a carcinoid
syndrome as well as a tumor size correlate with increased
metastatic potential [10, 11]. A precise detection of bio-
markers assessed by immunohistochemistry (IHC) ena-
bles the subtyping and accurate classification of PTCT
[12]. In general it is considered and it was described by
Abbosh et al. that caudal type homeobox 2 (Cdx-2), a
marker for neuroendocrine tumor cells originating from
GI tract, is negative in PTCT [9, 13]. Lee et al. and Bing
et al. described malignant germ cell tumors of the testes
stained positive for Cdx-2 suggesting precaution in mak-
ing a diagnosis in metastatic tumor with unknown origin
and thereby considering an occult testicular malignancy
rather than of GI origin [14, 15]. Albeit Atalay et al. dem-
onstrated a strong significant Cdx-2 staining, as it is
observed in tumor cells with GI origin, merely in testicu-
lar teratoma [16]. To the best of our knowledge, there is
in the literature only one reported case of Cdx-2 positive
PTCT [17]. In our case, the exceptionally rare Cdx-2
stain positivity was found as well, albeit no GI origin of
carcinoid tumor cells was detected. This data suggests
that the analytic specificity of Cdx-2 marker needs to be
assessed critically and distinct in each case. The standard
treatment of PTCT remains the radical inguinal orchiec-
tomy [6]. The recurrence of PTCT may occur up to
17 years after the initial diagnosis and treatment requir-
ing close clinical and imaging aftercare [18]. Since the
data is based on single cases there is no consensus about
general follow-up guidelines [6, 19]. In summary PTCT
has a good prognosis with the 5-year overall survival rate
of 78.7% and the 5-year specific survival rate of 84.3% and
should be alternatively considered in Cdx-2 positive met-
astatic tumor of unknown origin [19].

Conclusion
Primary testicular carcinoid tumor with Cdx-2 positive
stain outlines an exceptionally rare neoplastic entity.
The standard treatment of PTCT remains the radi-
 cal inguinal orchietomy. PTCT have a good progno-
sis albeit some prognostic factors increase metastatic
potential. The recurrence can appear almost 2 decades
after initial diagnosis requiring close clinical and imag-
ing aftercare.

Abbreviations
CD56: Cluster of differentiation 56; Cdx-2: Caudal type homeobox 2; DOTA-
TATE-PET/CT: Tetraazacyclododecanetetraacetic acid–DPhe1-Tyr3-octreotate
positron emission tomography/computed tomography; Ep4: Prostaglandin
E receptor 4; GI: Gastrointestinal tract; IHC: Immunohistochemistry; MIB-1:
Marker of proliferation Ki-67; NET: Neuroendocrine tumor; PTCT: Primary
testicular carcinoid tumor.
Acknowledgements
We are grateful to the patient for his contribution.

Authors’ contributions
E.W. and C.F.W. were involved in patient’s medical care. A.F performed and analyzed pathological studies. E.W. and C.F.W. gathered detailed clinical information and analyzed data. E.W. and C.F.W. wrote the paper. E.W. and C.F.W. conceived of and directed the project. The manuscript was critically reviewed by all authors. All authors read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Ethics Committee approval was not required for individual anonymized data.

Consent for publication
The written informed consent was obtained from the patient for publication of anonymized data and accompanying images. A copy of the written consent was uploaded and is available for review by the Editor.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Medicine IV, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 2 Institute of Surgical Pathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 3 Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany.

Received: 2 July 2020 Accepted: 4 December 2020
Published online: 14 December 2020

References
1. Yao JC, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–59.
3. Wang WP, et al. Primary carcinoid tumors of the testis: a clinicopathologic study of 29 cases. Am J Surg Pathol. 2010;34:519–24.
4. Kato N, et al. Primary carcinoid tumor of the testis: Immunohistochemical, ultrastructural and FISH analysis with review of the literature. Pathol Int. 2003;53:680–5.
5. Berdis JS, Mostofi FK. Carcinoid tumors of the testis. J Urol. 1977;118:777–82.
6. Stroosma OB, Delaere KP. Carcinoid tumours of the testis. BJU Int. 2008;101:1101–5.
7. D’Arrigo L, et al. Primary carcinoid tumour of the testis: a case-report. Arch Ital Urol Androl. 2014;86:231–2.
8. Mai KT, Park PC, Yazidi HM, Carlier M. Leydig cell origin of testicular carcinoid tumour: immunohistochemical and electron microscopic evidence. Histopathology. 2006;49:548–9.
9. Abbosh PH, et al. Germ cell origin of testicular carcinoid tumors. Clin Cancer Res. 2008;14:1393–6.
10. Zavala-Pompa A, et al. Primary carcinoid tumor of testis: immunohistochemical, ultrastructural, and DNA flow cytometric study of three cases with a review of the literature. Cancer. 1993;72:1726–32.
11. Penke M. Primary neuroendocrine tumor of the testis and osseous, cardiac, and lymph node metastases in a young patient. Case Rep Oncol. 2014;7:815–8.
12. Duan K, Mete O. Algorithmic approach to neuroendocrine tumors in targeted biopsies: practical applications of immunohistochemical markers. Cancer Cytopathol. 2016;124:871–84.
13. Lin F, Liu H. Immunohistochemistry in undifferentiated neoplasm/tumor of uncertain origin. Arch Pathol Lab Med. 2014;138:583–610.
14. Lee MJ, Vogt AP, Hisao W, Osunkoya AO. CDX-2 expression in malignant germ cell tumors of the testes, intratubular germ cell neoplasia, and normal seminiferous tubules. Tumour Biol. 2012;33:2185–8.
15. Bing Z, Pasha T, Tomaszewski JE, Zhang P. CDX2 expression in yolk sac component of testicular germ cell tumors. Int J Surg Pathol. 2009;17:373–7.
16. Oz Atalay F, AytaçVuruskan B, Vuruskan H. CDX2 immunostaining in primary and metastatic germ cell tumours of the testis. J Med Genet. 2016;44:1323–30.
17. AboZahr R, et al. Primary carcinoid tumor of the testis: a case report and review of the literature. Case Rep Urol. 2018;2018:3614387.
18. Hayashi T, et al. Primary carcinoid of the testis associated with carcinoid syndrome. Int J Urol. 2001;8:522–4.
19. Amine MM, et al. Neuroendocrine testicular tumors: a systematic review and meta-analysis. Curr Urol. 2017;10:15–25.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.